Nitroimidazole (Chagas)
objective
Generate new drug candidates for the treatment of Chagas to be assessed in clinical trials
project start
2012
project status
Completed
last phase of drug development
Drug Discovery
Translational research
Clinical trials
Registration & access
updated 31 Aug 2015
Share on linkedin
Share on twitter
Share on facebook
Share on email
Share on print
An opportunistic approach has been undertaken to assess compounds issuing from the VL-2098 back-up programme (nitroimidazooxazine series) showing activity against T. cruzi in vitro, evaluating the most promising candidates in in vivo models of Chagas disease. Two VL lead back-ups belonging to different sub-series (7-substituted nitroimidazooxazines and PA-824 analogues) are active and have been selected for further assessment against Chagas disease in the new bioluminescence in vivo model at LSHTM.
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.
